Greg Crescenzi, Chief Commercial Officer

April 12 | 11:15am | Dark Horse Consulting Ballroom

Cambridge, MA


In-Person Presentation

Kytopen, an MIT spin-out, is a transformative biotechnology company that offers a customizable yet scalable multi-solution platform, which seamlessly links the discovery, development, and manufacturing phases of cell engineering. Flowfect®, a gentle, non-viral delivery method unlocks new therapeutic approaches, by engineering immune cells with minimal disruption, preserving the functionality and viability of human cells and enhancing the cell’s biology. The Flowfect® platform accelerates therapies from the bench to clinical through flexibility and scalability, which drives higher cell yields, faster approvals, and better outcomes from potentially curative cell-based treatments. Kytopen’s goal is to enable simple and efficient non-viral manufacturing of cell therapies in days versus weeks to increase access to many more patients. We are on track to launch our Flowfect® Tx for cGMP-compliant cell therapy manufacturing in 2022 as we move towards treating the first human patient with Flowfect® engineered cells.

By using this website you agree to accept our Privacy Policy and Terms & Conditions